Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study

Front Pediatr. 2022 Dec 12:10:1083730. doi: 10.3389/fped.2022.1083730. eCollection 2022.

Authors

Ying Wu¹, Yanming Li², Jia Fan¹, Peijing Qi¹, Wei Lin¹, Jie Yang¹, Huiqing Liu¹, Xiaoling Wang², Huyong Zheng¹, Tianyou Wang¹, Ruidong Zhang¹

Affiliations

¹ Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
² Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

Abstract

[This corrects the article DOI: 10.3389/fped.2022.1034373.].

Keywords: b-cell acute lymphoblastic leukemia; blinatumomab; minimal residual disease; pediatric; real world.

© 2022 Wu, Li, Fan, Qi, Lin, Yang, Liu, Wang, Zheng, Wang and Zhang.

Publication types

Published Erratum